Kadmon Pharmaceuticals is our wholly owned, fully integrated commercial operation. Kadmon Pharmaceuticals will support the future commercialization of our clinical product candidates once approved.
Kadmon currently markets and promotes CLOVIQUE, a product developed in-house at Kadmon which is a trientine hydrochloride. For more information, see clovique.com.
For product inquiries or to report an adverse event or product quality complaint for a Kadmon marketed product, please call 1.877.377.7862. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1.800.FDA.1088.
Consumer Product Safety Improvement Act (CPSIA) Certification
In accordance with the CPSIA of 2008, Kadmon certifies that our product’s child-resistant packaging comply with the standards established under the Poison Prevention Packaging Act of 1970 as amended. To receive a copy of a CPSIA certificate for a Kadmon product, please contact Medical Information at 1.877.377.7862 or email@example.com.